Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trial

Official title:

Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06102447
• Other study ID #: SCCHEC-02-2023-076
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 1, 2023
• Est. completion date: January 1, 2026

Study information

• Verified date: October 2023
• Source: Sichuan Cancer Hospital and Research Institute
• Contact: Yangkun Luo
• Phone: 13518161979
• Email: 621199521[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The enrolled head and neck squamous cell carcinoma patients in this study received high-dose multiday chemotherapy with cisplatin and synchronous radiation therapy, which had a high risk of nausea and vomiting. On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting. The aim of this study is to evaluate the antiemetic effect of Netopitam Palonosetron capsules and to explore the effectiveness of using Netopitam Palonosetron capsules again for antiemetic treatment during the study period when breakthrough vomiting occurs.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 36
• Est. completion date: January 1, 2026
• Est. primary completion date: January 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female, aged 18-75 years old;

2. Head and neck tumors confirmed by histology or cytology (including oral cancer, oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer);

3. Receive radical synchronous radiotherapy and chemotherapy;

4. The Eastern Oncology Collaborative Group (ECOG) physical fitness score of the subjects was = 2 points;

5. Adequate organ and bone marrow function;

6. The expected life is at least 12 weeks;

7. Pregnant or fertile patients (male or female) use reliable contraceptive measures;

8. When screening female patients with potential pregnancy, the pregnancy test must be negative;

9. The subjects voluntarily and strictly comply with the requirements of the research protocol and sign a written informed consent form.

Exclusion Criteria:

1. Recurrent and metastatic head and neck tumors;

2. Previously underwent tumor resection surgery for treatment;

3. Patients with platinum drug intolerance;

4. Receiving any known or potential antiemetic medication within 24 hours prior to the first day, or experiencing symptoms of vomiting, retching, or mild nausea within 24 hours prior to the first day;

5. Take NK1(neurokinin-1) receptor antagonists or any study medication within 4 weeks before the start of the experiment;

6. Use CYP3A4 inducer within 4 weeks before chemotherapy, and use CYP3A4 substrate or strong or moderate CYP3A4 inhibitor within 1 week;

7. Serious cardiovascular, pulmonary, diabetes, mental and other diseases;

8. Pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures;

9. Drug and/or alcohol abuse;

10. Hypocalcemia or any other condition that may cause vomiting;

11. There are significant factors that affect the absorption of oral medication, such as chronic diarrhea and intestinal obstruction;

12. The subject has allergic reactions to Netopitam Palonosetron capsules or any of their excipients;

13. Within 30 days prior to the baseline visit, the subject participated in another clinical study and used any exploratory drugs or devices; Allow participation in observational research;

14. The researcher determines other situations that may affect the progress of clinical research and the determination of research results.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Carcinoma (HNSCC)
• Squamous Cell Carcinoma of Head and Neck
• Vomiting

Intervention

Drug:
• Netopitam Palonosetron capsules and dexamethasone
On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.

Locations

Country	Name	City	State
China	Sichuan Cancer Hospital and Research Institute	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Sichuan Cancer Hospital and Research Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The complete response rate during synchronous radiotherapy and chemotherapy (defined as no vomiting episodes and no emergency medication).		1 month
Secondary	No significant nausea rate during synchronous radiotherapy and chemotherapy		1 month
Secondary	Nausea free rate during synchronous radiotherapy and chemotherapy		1 month
Secondary	No vomiting rate during synchronous radiotherapy and chemotherapy		1 month
Secondary	The rate of non emergency medication during synchronous radiotherapy and chemotherapy		1 month
Secondary	The prevalence and severity of oral/oropharyngeal mucositis during synchronous radiotherapy and chemotherapy		1 month
Secondary	Successful rescue rate of breakthrough vomiting: (defined as no vomiting within 48 hours)		1 month
Secondary	Evaluate the impact of medication on patients' daily activities of life (evaluated based on the nausea and vomiting questionnaire FLIE)		1 month